Name: SLXNW Income Statement - Silexion Therapeutics Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

SLXNW - Silexion Therapeutics Corp.

USD | NASDAQ | Healthcare

SLXNW Income Statement - Silexion Therapeutics Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q3 FY 23	Q2 FY 23
Revenues
Revenues	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses
Research & Development	1.4	3.4	2.2	1.0	0.6	0.9	3.2	0.8	1.0	0.5	1.2
Selling General & Administrative	-	-
Operating Income
Operating Income	(2.7)	(4.4)	(3.3)	(2.3)	(1.7)	(1.9)	(8.0)	(1.4)	(1.3)	(0.7)	(1.4)
Non-Operating
Interest Income	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Interest Expense	0.0	0.1	0.0
Tax & Net
Income Tax Expense	-	-	0.0	0.0	-	0.0	0.0	0.0	0.0	0.0	0.0
Net Income From Continuing Ops	(2.7)	(4.4)
Per Share
EPS Basic	0.85	-	2.88	4.32	3.84	-	274.25	197.80	12.29	0.78	6.54
EPS Diluted	0.85	-	2.88
Supplementary Data
EBITDA	(2.7)	(4.4)	(3.3)	(2.3)	(1.6)	(1.9)	(8.0)	(1.4)	(1.2)	(0.7)	(1.4)
EBIT	(2.7)	(4.4)	(3.3)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023
Revenues
Revenues	-	-	-	-
Cost of Revenue	-	-	-	-
Gross Profit	-	-	-	-
Operating Expenses
Research & Development	7.9	7.1	5.8	3.7
Selling General & Administrative	-	-	-	-
Selling & Marketing	-	-	-
Operating Income
Operating Income	(12.7)	(11.6)	(12.6)	(4.7)
Non-Operating
Interest Income	0.2	0.2	0.0	0.2
Interest Expense	0.4	0.4	3.9	0.5
Income From Equity Investments	-	-	-
Tax & Net
Income Tax Expense	-	0.0	0.0	0.0
Net Income From Continuing Ops	(12.9)	(11.9)	(16.5)	(5.1)
Net Income From Discontinued Ops	-	-	-
Per Share
EPS Basic	2.30	8.96	394.94	44.23
EPS Diluted	2.30	8.96	394.94	44.23
Shares Basic	3.2	1.3	0.0	0.1
Supplementary Data
EBITDA	(12.7)	(11.6)	(12.5)	(4.6)
EBIT	(12.7)	(11.6)	(12.6)	(4.7)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)